Literature DB >> 10219011

Quality of life and Parkinson's disease.

P A Koplas1, H B Gans, M P Wisely, M Kuchibhatla, T M Cutson, D T Gold, C T Taylor, M Schenkman.   

Abstract

BACKGROUND: People with Parkinson's disease (PD) have a progressive loss of function eventually leading to severe disability. Although PD would be expected to have a profound impact on an individual's psychosocial health, there is relatively limited research on its psychosocial effect. The purposes of this study were (a) to examine the relationships between physical disability, depression, and control beliefs and quality of life in people with PD and (b) to characterize how these psychosocial variables differ by stage of disease.
METHODS: Eighty-six individuals from five stages based on clinical disability, ages 51-87, were interviewed. Established instruments were used to measure physical disability, depression, and control beliefs. Quality of life (QOL) was rated on a 5-point Likert scale.
RESULTS: A multivariable regression model including physical disability, stage of disease, depression, mastery, and health locus of control predicted QOL (R2 = 0.48), with mastery as the only significant predictor (p = .0001). There were significant differences by PD stage for all variables (p < .05).
CONCLUSIONS: Mastery predicted quality of life in individuals with PD even when depression and physical disability were included in the model. Differences in psychosocial variables by stage of PD suggest that the psychosocial profile of PD patients may change as the disease progresses.

Entities:  

Mesh:

Year:  1999        PMID: 10219011     DOI: 10.1093/gerona/54.4.m197

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  9 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Authors:  Alexander Khlebtovsky; Amihai Rigbi; Eldad Melamed; Ilan Ziv; Israel Steiner; Alona Gad; Ruth Djaldetti
Journal:  J Neural Transm (Vienna)       Date:  2012-03-22       Impact factor: 3.575

3.  Measuring outcomes in Parkinson's disease: a multi-perspective concept mapping study.

Authors:  Catharina Sjödahl Hammarlund; Maria H Nilsson; Peter Hagell
Journal:  Qual Life Res       Date:  2011-08-26       Impact factor: 4.147

4.  What are the determinants of quality of life in people with cervical dystonia?

Authors:  Y Ben-Shlomo; L Camfield; T Warner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

5.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

6.  Self-management rehabilitation and health-related quality of life in Parkinson's disease: a randomized controlled trial.

Authors:  Linda Tickle-Degnen; Terry Ellis; Marie H Saint-Hilaire; Cathi A Thomas; Robert C Wagenaar
Journal:  Mov Disord       Date:  2010-01-30       Impact factor: 10.338

7.  Psychiatric morbidity, cognitive dysfunction and quality of life in drug-naive patients with Parkinson's disease: A comparative study.

Authors:  Subhendu Shekhar Dhar; Jitendra Jeenger; Vikas Singroha; Manu Sharma; Devendra Mohan Mathur
Journal:  Ind Psychiatry J       Date:  2019-12-11

8.  Health literacy and quality of life among Iranian pregnant women: The mediating role of health locus of control.

Authors:  Marjan Mirzania; Abdoljavad Khajavi; Akram Kharazmi; Mahdi Moshki
Journal:  Med J Islam Repub Iran       Date:  2020-12-01

9.  Clinical aspects of palliative care in advanced Parkinson's disease.

Authors:  Johan Lokk; Ahmad Delbari
Journal:  BMC Palliat Care       Date:  2012-10-25       Impact factor: 3.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.